Leqembi

© Reuters. FILE PHOTO: The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai/Handout via REUTERS/File Photo By Leroy Leo and Julie Steenhuysen (Reuters) - A panel of expert…

A panel of independent advisors to the Food and Drug Administration is meeting Friday to make a recommendation on whether the Alzheimer's drug Leqembi, made by Eisai and Biogen, should receive full approval.The FDA is not required to follow…

The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023.Eisai | ReutersThe new Alzheimer's antibody treatment Leqembi could cost Medicare up to $5 billion per year, according to research…

Chiquita Brooks-LaSure testifies before the Senate Finance Committee during her nomination hearing to be administrator of the Centers for Medicare & Medicaid Services in Washington on Thursday, April 15, 2021.Caroline Brehman | CQ-Roll…

Research at BiogenSource: BiogenAlzheimer's patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai shows. The Japanese drugmaker and its partner Biogen last week released an…

© Reuters. FILE PHOTO: The Alzheimer's drug Leqembi is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai/Handout via REUTERS By Ahmed Aboulenein WASHINGTON(Reuters) - The Alzheimer's Association has…

The Veterans' Health Administration will cover Eisai and Biogen's Alzheimer's treatment Leqembi for some patients, the companies announced on Monday.In a statement, Eisai said veterans in the early stages of the disease who meet VHA…

Andrew Brookes | Image Source | Getty ImagesThe Food and Drug Administration will make a decision on whether to fully approve Eisai's and Biogen's Alzheimer's treatment Leqembi by July 6, the companies announced on Monday.Leqembi is an…

Medicare will not provide broader coverage of the Alzheimer's drug Leqembi until it receives more evidence that the treatment is reasonable and necessary, according to the federal agency that runs the program for seniors.The Centers for…

Tek Image/science Photo Library | Science Photo Library | Getty ImagesJapanese drugmaker Eisai expects the Food and Drug Administration to fully approve its Alzheimer's treatment Leqembi this summer, which would expand access to the pricey…